agilon health, inc. revised earnings guidance for the year ending December 31, 2024. For the year, the company expects revised total revenues to be in the range of $6,125 million to $6,175 million compared to previously expected total revenues to be in the range of $6,350 million to $6,465 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.52 USD | +2.68% |
|
-5.51% | -48.05% |
06-05 | Transcript : Agilon health, inc. Presents at The 44th Annual William Blair Growth Stock Conference, Jun-05-2024 11:20 AM | |
06-05 | Agilon Health Names Jeff Schwaneke CFO | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-48.05% | 2.68B | |
-30.88% | 2.55B | |
-28.27% | 2.41B | |
-47.40% | 227M | |
-4.03% | 213M | |
-53.67% | 152M | |
-37.43% | 107M |
- Stock Market
- Equities
- AGL Stock
- News agilon health, inc.
- Agilon health, inc. Revises Earnings Guidance for the Year Ending December 31, 2024